Buy GHK-Cu Copper Peptide for Laboratory Research

GHK-Cu designates a complex of the tripeptide glycyl-L-histidyl-L-lysine with copper(II). GHK records the sequence Gly-His-Lys. The sequence and its copper-bound description are chemically distinct reference layers. Literature describes the sequence as endogenous, but that description supplies neither a concentration nor an identity assignment for commercial material.

The public-register values below are established for the free, L-configured tripeptide. The short name GHK-Cu alone does not resolve GHK-to-copper ratio, counter-ion, hydration, protonation or charge representation.

These values describe database reference structures, not the commercial batch. Values for the free peptide must not be transferred to the copper complex. Naming or a register match does not authenticate supplied material.

Chemical distinction in a cell model: Maquart et al. 1988 · PMID 3169264

The cited experiments address separate measurement classes. They do not establish a shared causal chain, primary molecular target, receptor interaction or direct binding claim. Even when observations appear in related fibroblast systems, culture conditions, timing, comparator and assay define what each publication can support.

Maquart and colleagues attributed their 1988 collagen-synthesis finding in cultured fibroblasts to the tripeptide–copper complex rather than the free tripeptide. That attribution describes the tested cell system; it is not a general substance property and supplies no transfer claim. Simeon and colleagues later measured MMP-2 expression in another fibroblast culture design. McCormack and colleagues examined VEGF and bFGF in a serum-free fibroblast model. Gruchlik and colleagues compared free Gly-Gly-His and Gly-His-Lys peptides with their copper complexes in measurements of TNF-α-dependent IL-6 secretion in normal human dermal fibroblasts.

Marker change, correlation and direct molecular interaction are different propositions. None should be inferred from another. Human-derived cells remain an in vitro model, and their origin does not turn a culture experiment into clinical evidence.

Endpoint sources: Simeon et al. 2000 · PMID 11045606 · McCormack et al. 2001 · PMID 11176716 · Gruchlik et al. 2012 · PMID 23285694

This section describes findings in controlled research and makes no statement about use. The records are ordered by model type: in vitro fibroblast cultures, a serum-free culture, human skin layers in vitro, and then a preclinical animal model. This is a wholly preclinical source set, with no human intervention study.

Row placement does not merge the studies. Reconciliation requires the original material description, model, controls, assay and endpoint for each record.

The PubMed source links for this chapter are provided within the model rows.

Free GHK and its copper(II) complex must remain distinct. The free tripeptide has the register values listed in Chapter 01; the complex has multiple public representations. Copper binding is a classification statement, not a statement of activity. A publication using one characterised reference material does not identify another material bearing the same short name.

This dossier is also separate from consumer-product framing. The penetration publication is an in vitro transport study in human skin layers, not a consumer study and not evidence for an effect after skin exposure. GLOW Blend and KLOW Blend are separate catalogue positions that list GHK-Cu as a component. That component relationship transfers neither analytical findings nor batch documentation between a blend and this single-substance position.

The evidence does not establish a molecular target, a unified pathway, clinical performance or properties of supplied material. The source set is preclinical. Human fibroblasts and human skin layers studied outside the body are not clinical evidence. Part of the review and bioinformatics literature concerning this substance comes from the same author group, so the number of related publications is not evidence of broader independent confirmation.

A further open point concerns endogenous occurrence. Historical literature describes the sequence as endogenous, but no accessible primary publication was verified that documents measurement method, sample size, age groups and concentrations for the frequently repeated plasma claim. Accordingly, this dossier makes no quantitative or age-related statement.

Model-boundary source: Hostynek et al. 2010 · transport study

Laboratories that buy GHK-Cu for a documented project should reconcile the precise designation, batch code and identity evidence with the released product specification and matching batch documentation. The records should attribute test date, method and finding to the relevant batch. A document without a matching batch identifier cannot substantiate supplied material.

Any purity statement must be batch- and method-specific. HPLC may describe a chromatographic profile or purity finding for the tested batch under the stated method; it does not establish blanket purity. For GHK-Cu, HPLC purity also does not answer the unresolved questions of stoichiometry, counter-ion, hydration, protonation or register representation. Chromatographic purity and molecular assignment remain separate analytical questions.

Published work documents model-specific measurements; supply records document material released to a laboratory. Neither substitutes for the other. This record makes no assertion about content amount, physical presentation, storage condition, temperature, stability period or shelf life.

Research use only. For laboratory research only. Not for human or veterinary use. Not intended to diagnose, treat, cure or prevent any disease. Not a medicinal product, food or cosmetic.